Breakthrough status in hand, Prosensa launches $78m IPO
This article was originally published in Scrip
Taking advantage of the US FDA's decision to grant a breakthrough therapy designation for its lead drug candidate drisapersen in partnership with GlaxoSmithKline, Dutch biotechnology firm Prosensa priced its US initial public offering at $13 per share for gross proceeds of $78 million.
You may also be interested in...
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.